| No. |
Characteristic |
Chronic Phase (n=79) |
Accelerated Phase (n= 15) |
Blast Crisis Phase (n=6) |
Total |
| |
|
Frequency |
% |
Frequency |
% |
Frequency |
% |
Frequency |
% |
| 1 |
Duration of illness before Imatinib therapy (in months) |
| |
<6 months |
52 |
65.8 |
11 |
73.3 |
5 |
83.3 |
68 |
68 |
| |
6-12 months |
8 |
10.1 |
0 |
0 |
1 |
0 |
9 |
9 |
| |
13-18 months |
2 |
2.5 |
1 |
6.7 |
0 |
16.7 |
3 |
3 |
| |
19-24 months |
1 |
1.3 |
0 |
0 |
0 |
0 |
1 |
1 |
| |
>24 months |
9 |
11.4 |
2 |
13.3 |
0 |
0 |
11 |
11 |
| |
Unknown |
7 |
8.9 |
1 |
6.7 |
0 |
0 |
8 |
8 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 2 |
Duration of illness before Imatinib therapy (in year) |
| |
<1 year |
60 |
75.9 |
11 |
73.3 |
6 |
100 |
77 |
77 |
| |
≥1 year |
12 |
17.1 |
3 |
20 |
0 |
0 |
15 |
15 |
| |
Unknown |
7 |
7 |
1 |
6.7 |
0 |
0 |
8 |
8 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 3 |
Previous treatment |
| |
HU |
54 |
68.4 |
10 |
66.7 |
3 |
50 |
67 |
67 |
| |
IM+HU |
3 |
3.8 |
0 |
0 |
0 |
0 |
3 |
3 |
| |
Others |
1 |
1.3 |
0 |
0 |
1 |
16.7 |
2 |
2 |
| |
Unknown |
21 |
26.6 |
5 |
33.3 |
2 |
33.3 |
28 |
28 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 4 |
Duration of Hidroxyurea therapy before Imatinib started |
| |
≤6 months |
38 |
70.4 |
5 |
50 |
2 |
66.7 |
45 |
67.2 |
| |
>6 months |
16 |
29.6 |
5 |
50 |
1 |
33.3 |
22 |
32.8 |
| |
Total |
54 |
100 |
10 |
100 |
3 |
100 |
67 |
100 |
| 5 |
Splenomegaly |
| |
<10 cm |
34 |
43 |
5 |
33.3 |
2 |
33.3 |
41 |
41 |
| |
≥10 cm |
45 |
57 |
10 |
66.7 |
4 |
66.7 |
59 |
59 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 6 |
Blast cells (in%) |
| |
<5 |
61 |
77.2 |
3 |
20 |
0 |
0 |
64 |
64 |
| |
5-10 |
18 |
22.8 |
6 |
40 |
0 |
0 |
24 |
24 |
| |
>10 |
0 |
0 |
6 |
40 |
6 |
100 |
12 |
12 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 7 |
Basophils (in%) |
| |
<5 |
40 |
50.6 |
8 |
53.3 |
6 |
100 |
54 |
54 |
| |
≥5 |
20 |
25.3 |
6 |
40 |
0 |
0 |
26 |
26 |
| |
Unknown |
19 |
24.1 |
1 |
6.7 |
0 |
0 |
20 |
20 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 8 |
White blood count (x/uL) |
| |
<4,500 |
7 |
8.9 |
0 |
0 |
0 |
0 |
7 |
7 |
| |
4,500-11,000 |
10 |
12.7 |
0 |
0 |
0 |
0 |
10 |
10 |
| |
>11,000 |
62 |
78.5 |
14 |
93.3 |
6 |
100 |
82 |
82 |
| |
Unknown |
0 |
0 |
1 |
6.7 |
0 |
0 |
1 |
1 |
| |
Total |
79 |
100 |
15 |
100 |
100 |
100 |
100 |
100 |
| 9 |
Platelets (1x103/uL) |
| |
<150 |
4 |
5.1 |
0 |
0 |
2 |
33.3 |
6 |
6 |
| |
150-400 |
23 |
29.1 |
3 |
20 |
3 |
50 |
29 |
29 |
| |
>400 |
52 |
65.8 |
8 |
53.3 |
1 |
16.7 |
61 |
61 |
| |
Unknown |
0 |
0 |
4 |
26.7 |
0 |
0 |
4 |
4 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 10 |
Sokal’s risk |
| |
Low |
26 |
32.9 |
2 |
13.3 |
0 |
0 |
28 |
28 |
| |
Intermediate |
21 |
26.6 |
1 |
6.7 |
0 |
0 |
22 |
22 |
| |
High |
32 |
40.5 |
12 |
80 |
6 |
100 |
50 |
50 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
| 11 |
Survival |
| |
Live |
74 |
93.7 |
13 |
86.7 |
2 |
33.3 |
89 |
89 |
| |
Dead |
5 |
6.3 |
2 |
13.3 |
4 |
66.7 |
11 |
11 |
| |
Total |
79 |
100 |
15 |
100 |
6 |
100 |
100 |
100 |
|
